

Product Sheet

ADCP FcγRIIa Jurkat Effector Cell Line


Catalog number: GM-C09467

Version 3.3.1.241213

ADCP, or antibody-dependent cellular phagocytosis, refers to the process by which immune cells expressing Fc receptors recognize and phagocytose target cells that are specifically bound by antibodies. FcγRIIa (CD32) is a receptor for the Fc region of immunoglobulin G (IgG) and belongs to the Fc receptor family.

FcγRIIa's signal transduction occurs via its short cytoplasmic tail. When it binds IgG, the receptor activates downstream pathways, recruiting and activating tyrosine kinases like Syk and Src family kinases. These kinases then activate phosphoinositide 3-kinase (PI3K) and Ras/MAPK pathways, resulting in increased intracellular calcium, cytokine release, and cell proliferation.

ADCP FcγRIIa Jurkat Effector Cell Line is a clonal stable Jurkat cell line constructed using lentiviral technology, constitutive expression of the FcγRIIa gene, along with signal-dependent expression of a luciferase reporter gene. When IgG binds to target cells and effector cells, it leads to the expression of luciferase, which can be used to evaluate the biological activity of antibodies in the mechanism of ADCP.



Specifications

Quantity	5E6 Cells per vial, 1 mL
Product Format	1 vial of frozen cells
Shipping	Shipped on dry ice
Storage Conditions	Liquid nitrogen immediately upon receipt

Recovery Medium	RPMI 1640+10% FBS+1% P.S
Growth medium	RPMI 1640+10% FBS+1% P.S+3.5 µg/mL Blasticidin+0.75 µg/mL Puromycin
Note	None
Freezing Medium	90% FBS+10% DMSO
Growth properties	Suspension
Growth Conditions	37°C, 5% CO ₂

Mycoplasma Testing	The cell line has been screened to confirm the absence of Mycoplasma species.
Safety considerations	Biosafety Level 2
Note	It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use.

Materials

Reagent	Manufacturer/Catalogue No.
RPMI 1640	gibco/C11875500BT
Fetal Bovine Serum	Cegrogen biotech/A0500-3010
Pen/Strep	Thermo/15140-122
Blasticidin	Genomeditech/ GM-040404
Puromycin	Genomeditech/ GM-040401
H_CLDN18.2(isoform2) CHO-K1 Cell Line	Genomeditech/ GM-C05273
Anti-CLDN18.2 hIgG1 Antibody(Zolbetuximab)	Genomeditech/ GM-34137AB
Human Fc gamma RII/CD32 Alexa Fluor® 488-conjugated Antibody	R&D SYSTEMS/FAB1330G
GMOne-Step Luciferase Reporter Gene Assay Kit	Genomeditech/ GM-040503

Figures




Figure 1 | Response to Anti-CLDN18.2 hIgG1 Antibody. Serial dilutions of the Anti-CLDN18.2 hIgG1 Antibody(Zolbetuximab) (Cat. [GM-34137AB](#)) and 1.5E5 cells/well of the ADCP FcγRIIa Jurkat Effector Cell Line (Cat. GM-C09467) were added to 1E4 cells/well of H_CLDN18.2 CHO-K1 cell line (Cat. [GM-C05273](#)) for 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. [GM-040503](#)). The maximum induction fold was approximately[8.4]. Data are shown by drug mass concentration.




Figure 2 | Response to Anti-CLDN18.2 hIgG1 Antibody. Serial dilutions of the Anti-CLDN18.2 hIgG1 Antibody(Zolbetuximab) (Cat. [GM-34137AB](#)) and 1.5E5 cells/well of the ADCP FcγRIIa Jurkat Effector Cell Line (Cat. GM-C09467) were added to 1E4 cells/well of H_CLDN18.2 CHO-K1 cell line (Cat. [GM-C05273](#)) for 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. [GM-040503](#)). The maximum induction fold was approximately[8.4]. Data are shown by drug molar concentration.




Figure 3 | The passage stability of response to Anti-CLDN18.2 hIgG1 Antibody. Serial dilutions of the Anti-CLDN18.2 hIgG1 Antibody(Zolbetuximab) (Cat. [GM-34137AB](#)) and 1.5E5 cells/well of the passage 5, 10, 20 and 30 of the ADCP FcγRIIa Jurkat Effector Cell Line (Cat. [GM-C09467](#)) were added to 1E4 cells/well of H_CLDN18.2 CHO-K1 cell line (Cat. [GM-C05273](#)) for 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. [GM-040503](#)). Data are shown by drug mass concentration.




Figure 4 | ADCP FcγRIIa Jurkat Effector Cell Line (Cat. [GM-C09467](#)) was determined by flow cytometry using Human Fcγ RII/CD32 Alexa Fluor® 488-conjugated Antibody (R&D/FAB1330G).

Cell Recovery

Recovery Medium: RPMI 1640+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

- a) Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).
- b) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- c) Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.
- d) Resuspend cell pellet with the recommended complete medium. And dispense the suspension into 1 - 2 T-25 culture flasks.
- e) Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

- a) Centrifuge at 176 x g for 3 minutes to collect cells.
- b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
- c) Aliquot 1 mL into each vial.
- d) Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640+10% FBS+1% P.S+3.5 µg/mL Blasticidin+0.75 µg/mL Puromycin

Approximately 48-72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics. If cells are not passaged within 48 hours, it is recommended to add some fresh recovery medium and place the flask horizontally.

- a) When the cell density reaches 1.5 - 2E6 cells/mL, subculture the cells. Do not allow the cell density to exceed 2E6 cells/mL.
- b) It is recommended to use T-25 flasks for subculturing.
- c) These cells are suspension cells, and it is recommended to use the "half-medium change" method to maintain optimal cell conditions during passaging.
- d) During passaging, you can directly add fresh growth medium to the culture flask, gently pipette to resuspend the cells, and then transfer the cell suspension to a new T-25 flask for continued culture.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 3E5 and 1E6 viable cells/mL.

Medium Renewal: Every 2 to 3 days

Notes

- a) These cells are sensitive to density, so please ensure that the cell density is maintained within an appropriate range during culture and subculturing.

- b) During the first passage, pay attention to the nutrient supply; if not subculturing, make sure to add fresh recovery medium every other day as needed.

Related Products

FcγR	
Cynomolgus_FcRn MDCK Cell Line	H_FCGR1A(CD64) CHO-K1 Cell Line
H_FCGR1A(CD64) HEK-293 Cell Line	H_FCGR2A(CD32A) CHO-K1 Cell Line
H_FCGR2B(CD32B) CHO-K1 Cell Line	H_FCGR3A(CD16a) 158F CHO-K1 Cell Line
H_FCGR3A(CD16a) 158V CHO-K1 Cell Line	H_FCGR3B(CD16b) CHO-K1 Cell Line
H_FcRn CHO-K1 Cell Line	H_FcRn MDCK Cell Line
Mouse_FcRn MDCK Cell Line	
Anti-FcRn hIgG4 Reference Antibody(Rozabio)	Anti-H_FcRn IgG4 Antibody(Rozanolixizumab)
Anti-Mouse CD1632 mIgG2b Antibody(2.4G2)	
ADCCP	
ADCC FcγRIIIa(158F) Jurkat Effector Cell Line	ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line
ADCC FcγRIIIa(158V) Jurkat Effector Cell Line	ADCC M_FcγRIV Jurkat Effector Cell Line
ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line	ADCP FcγRIIa R131 Jurkat Effector Cell Line
ADCP FcγRIIb Jurkat Effector Cell Line	

Limited Use License Agreement

Genomeditech (Shanghai) Co., Ltd grants to the Licensee all intellectual property rights, exclusive, non-transferable, and non-sublicensable rights of the Licensed Materials; Genomeditech (Shanghai) Co., Ltd will retain ownership of the Licensed Materials, cell line history packages, progeny, and the Licensed Materials including modified materials.

Between Genomeditech (Shanghai) Co., Ltd, and Licensee, Licensee is not permitted to modify cell lines in any way. The Licensee shall not share, distribute, sell, sublicense, or otherwise provide the Licensed Materials, or progenitors to third parties such as laboratories, departments, research institutions, hospitals, universities, or biotechnology companies for use other than for the purpose of outsourcing the Licensee's research.

Please refer to the Genomeditech Cell Line License Agreement for details.